Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center
ASCO/ESMO 2020 - KEYNOTE 048 Study Update, What Have We Learned?
dbrock
ASCO/ESMO 2020 - KEYNOTE 048 Study Update, What Have We Learned?
First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC
First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC
Image
We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.
Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program.
Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.
For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss what we have learned from Keynote 048: First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC
We thank Varian for their support of this program!
To join the conversation, visit https://cancergrace.org/forum.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
In this 2nd series of videos, Michael Herman takes us through the story of his diagnosis, his struggles with treatment options, his clinical trial and his learning curve.
Thank you to our Sponsors! #lilly #exelixis
Article
Head and neck cancers linked to human papillomavirus (HPV) are very different from those caused by tobacco or alcohol. The good news is that HPV-positive cancers usually respond better to treatment and often have better outcomes.
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
Online Community
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Recent Comments
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: